Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec) ( DrugBank: Bevacizumab, Imatinib )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 87 | Pulmonary veno-occlusive disease | 1 |
87. Pulmonary veno-occlusive disease
Clinical trials : 3 / Drugs : 4 - (DrugBank : 3) / Drug target genes : 4 - Drug target pathways : 45
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00891527 (ClinicalTrials.gov) | October 2008 | 30/4/2009 | Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis | Adjunct Targeted Biologic Inhibition in Children With Multivessel Intraluminal Pulmonary Vein Stenosis | Pulmonary Veno Occlusive Disease | Drug: Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec) | Boston Children's Hospital | NULL | Completed | N/A | N/A | All | 50 | Phase 1/Phase 2 | United States |